Skip to main content

Table 1 Baseline a characteristics of patients included in analyses of rapid progression, according to availability of data

From: Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study

   Patients with eGFR data available ≥4 years follow-up ≥3 years follow-up
    Unrestrictedf ≥3 eGFR per year ≥2 eGFR per year Unrestricted* ≥3 eGFR per year ≥2 eGFR per year
Eligible patients Number (%) 22603 (100) 13061 (57.8) 3655 (16.2) 8298 (36.7) 16165 (71.5) 6375 (28.2) 12283 (54.3)
Average eGFR Median (IQR) 109 (99–123) 108 (99–122) 107 (98–121) 108 (99–121) 109 (99–122) 108 (99–122) 108 (99–122)
eGFR >120 ml/min Number (%) 6613 (29.3) 3616 (27.7) 943 (26) 225 (27) 4562 (28.1) 1723 (27) 3412 (28)
Gender Male 16438 (72.7) 9335 (71.5) 2622 (71.7) 5999 (72.3) 11613 (71.8) 4617 (72.4) 8906 (72.5)
Race White 10573 (46.8) 6343 (48.6) 1631 (44.6) 3835 (46.2) 7469 (46.2) 2584 (40.5) 5454 (44.4)
Black 1806 (8.0) 1141 (8.7) 354 (9.7) 720 (8.7) 1346 (8.3) 581 (9.1) 1023 (8.3)
Other 510 (2.3) 306 (2.3) 103 (2.8) 197 (2.4) 385 (2.4) 155 (2.4) 294 (2.4)
Unknown 9714 (43.0) 5271 (40.4) 1567 (42.9) 3546 (42.7) 6965 (43.1) 3055 (47.9) 5512 (44.9)
Age group >50 years 2238 (9.9) 1280 (9.8) 410 (11.2) 868 (10.5) 1641 (10.2) 702 (11.0) 1309 (10.7)
Hypertensionb Yes 2519 (11.1) 1526 (11.7) 494 (13.5) 1030 (12.4) 1865 (11.5) 784 (12.3) 1458 (11.9)
Diabetesc Yes 659 (2.9) 428 (3.3) 145 (4.0) 290 (3.5) 517 (3.2) 237 (3.7) 413 (3.4)
Mode of HIV acquisition Homosexual 10006 (44.3) 5642 (43.2) 1611 (44.1) 3710 (44.7) 7028 (43.5) 2876 (45.1) 5487 (44.7)
IDU 3058 (13.5) 1783 (13.7) 450 (12.3) 1019 (12.3) 2196 (13.6) 740 (11.6) 1540 (12.5)
Heterosexual 8095 (35.8) 4865 (37.3) 1385 (37.9) 3081 (37.1) 5952 (36.8) 2359 (37.0) 4499 (36.6)
Other 1444 (6.4) 771 (5.9) 209 (5.7) 488 (5.9) 989 (6.1) 400 (6.3) 757 (6.2)
BMI at study entry (kg/m2) <18 633 (2.8) 345 (2.6) 91 (2.5) 216 (2.6) 440 (2.7) 169 (2.7) 330 (2.7)
≥18, <26 15865 (70.2) 9310 (71.3) 2542 (69.6) 5877 (70.8) 11473 (71.0) 4466 (70.1) 8717 (71.0)
≥26, <30 3716 (16.4) 2231 (17.1) 677 (18.5) 1466 (17.7) 2727 (16.9) 1106 (17.4) 2088 (17.0)
≥30 1423 (6.3) 845 (6.5) 238 (6.5) 536 (6.5) 1037 (6.4) 398 (6.2) 774 (6.3)
Unknown 966 (4.3) 330 (2.5) 107 (2.9) 203 (2.5) 488 (3.0) 236 (3.7) 374 (3.0)
Hepatitis Cd positive Yes 2765 (12.2) 1605 (12.3) 400 (10.9) 910 (11.0) 1958 (12.1) 653 (10.2) 1346 (10.6)
Hepatitis Be positive Yes 2773 (12.3) 1551 (12.4) 450 (12.3) 1001 (12.1) 1971 (12.2) 816 (12.8) 1501 (12.2)
Smoking status Current 9544 (42.2) 5554 (42.5) 1467 (40.1) 3445 (41.5) 6930 (42.9) 2571 (40.3) 5198 (42.3)
Previous 3930 (17.4) 2426 (18.6) 681 (18.6) 1557 (18.8) 2923 (18.1) 1193 (18.7) 2248 (18.3)
Never 5824 (25.8) 3599 (27.6) 1086 (29.7) 2332 (28.1) 4314 (26.7) 1726 (27.1) 3299 (26.9)
Unknown 3305 (14.6) 1482 (11.4) 421 (11.5) 964 (11.6) 1998 (12.4) 885 (13.9) 1538 (12.5)
Current CD4 count (cells/mm3) <200 2823 (12.5) 1435 (11.0) 482 (13.2) 940 (11.3) 1831 (11.3) 833 (13.1) 1424 (11.6)
200-349 4912 (21.7) 2797 (21.4) 826 (22.6) 1807 (21.8) 3427 (21.2) 1444 (22.7) 2641 (21.5)
350-499 5565 (24.6) 3294 (25.2) 963 (26.4) 2109 (25.4) 4049 (25.1) 1632 (25.6) 3078 (25.1)
≥500 9145 (40.5) 5492 (42.1) 1371 (37.5) 3417 (41.2) 6779 (41.9) 2432 (38.2) 5079 (41.4)
  Missing 158 (0.7) 43 (0.3) 13 (0.4) 25 (0.3) 79 (0.5) 34 (0.5) 61 (0.5)
  1. Abbreviations: eGFR, estimated glomerular filtration rate; IDU, injecting drug user;
  2. aBaseline was defined as the defined as the time, during prospective follow-up, of the first eGFR measurement on or after 1 January 2004.
  3. bHypertension was defined as a blood pressure of ≥150/≥100 mmHg or use of antihypertensive drugs and ace inhibitors.
  4. cDiabetes was defined as receipt of antidiabetic treatment or verification of diabetes in a case report form.
  5. dHepatitis C was defined as detection of antibody to HCV plus detection or unknown presence of HCV RNA.
  6. eHepatitis B was defined as detection of HBV surface antigen, detection of HBV e antigen, or detection of HBV DNA plus antibody to HBV e antigen.
  7. fUnrestricted was defined as no restriction concerning the number of eGFR measurements obtained per year.